Skip to main content

Drug Interactions between probenecid and Ravicti

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

probenecid glycerol phenylbutyrate

Applies to: probenecid and Ravicti (glycerol phenylbutyrate)

MONITOR CLOSELY: Probenecid may inhibit the renal excretion of metabolites of phenylbutyrate, including phenylacetate (PAA) and phenylacetylglutamine (PAGN). PAA is associated with neurotoxic effects such as somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, memory impairment, tremor, peripheral neuropathy, and seizures.

MANAGEMENT: Since plasma PAA and urinary PAGN levels may be used to help guide dosing of phenylbutyrate therapy, caution is advised if probenecid is coadministered. The potential for increased risk of PAA-induced neurotoxicity should also be considered. The prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine) recommends avoiding concomitant use of probenecid.

References

  1. (2001) "Product Information. Buphenyl (sodium phenylbutyrate)." Horizon Therapeutics USA Inc
  2. (2013) "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc
  3. (2022) "Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol)." Amylyx Pharmaceuticals, 1
  4. (2022) "Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine)." Innomar Strategies Inc.
View all 4 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer